CRISPR-Cas method

Overview

The CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats–CRISPR-associated protein) method is a prokaryote-derived adaptive immune mechanism that has been repurposed as a precise, programmable genome editing technology. At its core, the system relies on a guide RNA (gRNA) that directs a Cas nuclease—most commonly Cas9, though alternative effectors such as CRISPR-Cas12a are increasingly employed—to a complementary DNA sequence adjacent to a protospacer adjacent motif (PAM). Upon target recognition, the nuclease introduces a site-specific double-strand break (DSB), which cells repair through error-prone non-homologous end joining (NHEJ) or high-fidelity homology-directed repair (HDR), enabling gene disruption, correction, or insertion. Beyond canonical nuclease activity, derivative platforms including base editing, prime editing, and CRISPR interference (CRISPRi) extend the toolkit to single-nucleotide conversions, precise insertions, and transcriptional repression without inducing DSBs, substantially broadening the therapeutic and research utility of the system.

The biological significance of CRISPR-Cas spans basic science, translational medicine, and agriculture. Its programmability—determined entirely by the gRNA sequence—allows rapid retargeting to virtually any genomic locus in any organism, from bacteria and yeast to plants, invertebrates, and humans. This versatility has made CRISPR-Cas a cornerstone technology for functional genomics screens, disease modeling, and the development of next-generation gene therapies targeting conditions ranging from monogenic disorders such as beta-thalassemia, Wilson disease, Duchenne muscular dystrophy, and hemophilia, to complex polygenic diseases including cancer, Alzheimer's disease, and Parkinson's disease.

Focus of Latest Publications

Therapeutic Gene Editing in Human Disease

A major thrust of recent CRISPR-Cas research concerns its translation into curative therapies for inherited and acquired diseases. In the context of Parkinson's disease and Alzheimer's disease, reviews have examined how base editing, prime editing, and canonical CRISPR-Cas9 can be deployed to correct or silence disease-associated loci, with prime editing receiving particular attention for its capacity to install precise mutations without DSBs, reducing the risk of chromosomal instability. For Alzheimer's disease, gene editing strategies targeting apolipoprotein E4 and Beta amyloid processing genes have been explored alongside stem cell therapy, with CRISPR-Cas9 proposed as a means to correct mutations in patient-derived stem cells before autologous transplantation.

In Duchenne muscular dystrophy, a CRISPR-Cas9-based strategy was developed to disrupt repressor binding sites in the utrophin promoter, enhancing utrophin expression as a functional surrogate for the absent dystrophin protein—demonstrating that transcriptional activation, not only gene knockout, is a viable therapeutic modality. For Huntington's disease, a self-inactivating AAV-CRISPR approach delivered at different ages achieved sustained reduction of mutant HTT in a BAC226Q mouse model, addressing concerns about prolonged Cas9 expression and immune activation. Wilson disease patient-specific induced pluripotent stem cells carrying the H1069Q point mutation were corrected using CRISPR-Cas9-mediated HDR, illustrating the system's capacity for single-nucleotide precision in clinically relevant cell types. Epidermolysis bullosa research has similarly leveraged Cas9 nickases to mitigate off-target genotoxicity while achieving therapeutic correction.

Hemophilia gene therapy has integrated CRISPR-Cas9 alongside adeno-associated viral vectors and lipid nanoparticles to achieve durable correction, with studies emphasizing long-term efficacy and improved quality of life as primary endpoints. In beta-thalassemia, CRISPR-Cas9 was applied to hematopoietic stem cells targeting the HBB FSC 36-37 (-T) mutation locus, with xenotransplantation experiments in NSG and NBSGW mice used to compare lentiviral vector transduction against CRISPR-mediated gene correction.

Oncology: Functional Screens and Therapeutic Targeting

Genome-wide CRISPR-Cas9 loss-of-function screens have become the dominant approach for identifying cancer dependencies. An in vivo screen targeting epigenetics-related factors in tumor-bearing mice treated with checkpoint inhibitor (anti-programmed cell death protein 1, anti-PD-1) identified chromobox 4 (CBX4) as a key negative regulator of the immune tumor microenvironment, demonstrating how CRISPR screens can nominate targets for cancer immunotherapy. A druggable CRISPR-Cas9 library screen identified isocitrate dehydrogenase 1 (IDH1) as the crucial mediator of chemoresistance in intrahepatic cholangiocarcinoma, directly informing the repurposing of the allosteric inhibitor ivosidenib. In renal cell carcinoma, a genome-wide CRISPR-Cas9 screen using oncogene-induced senescence as a functional readout identified Cyclin C (CCNC) as essential for PRCC-TFE3-driven tumorigenesis.

The application of CRISPR-Cas9 to pancreatic cancer has taken an unconventional therapeutic direction: simultaneous cancer-specific multi-target sgRNAs were used to induce multiple concurrent DSBs, exploiting the resulting chromosomal instability as a lethal insult selectively in tumor cells carrying somatic mutations, representing a proof-of-concept for CRISPR as a direct cytotoxic agent rather than merely a research tool. In chronic myeloid leukemia, CRISPR-Cas9-mediated knockout of STAT5A restored tyrosine kinase inhibitor sensitivity in resistant cell lines. AFP-knockout models in hepatocellular carcinoma cell lines generated via CRISPR-Cas9 revealed AFP's oncogenic role through the PI3K/Akt signaling pathway. In pediatric acute myeloid leukemia, CRISPR-Cas9-mediated RUNX1 knockout exposed stem cell-like transcriptional features and metabolic reprogramming. A genome-wide CRISPR-Cas9 screen for heat resistance in Bombyx mori identified BmM-ALP as an orchestrator of antioxidant response and metabolic adaptation.

Targeted Cancer Therapy reviews have highlighted CRISPR-Cas9 as a future strategy for durable anti-cancer effects, particularly for targeting VEGFA in diabetic retinopathy (using ionizable lipid nanoparticles for ocular delivery), TP53 restoration, and disruption of oncogenic signaling through messenger RNA targeting. A high-entropy alloy nanoplatform integrating CRISPR-Cas9 with gold, bismuth, platinum, silver, and palladium components, combined with tumor cell membranes for home-targeting, was developed for cocktail-sensitized radioimmunotherapy of lung metastases, exemplifying the convergence of materials science and gene editing.

Delivery Systems and Non-Viral Carriers

A critical bottleneck for CRISPR-Cas therapeutics remains safe and efficient delivery, and recent research has focused heavily on non-viral approaches. lipid nanoparticles have emerged as the leading non-viral carrier, with piperazine-derived diamine lipid nanoparticles achieving liver-targeted CRISPR-Cas9 delivery for durable PCSK9 knockout and consequent reduction of low-density lipoprotein cholesterol. Pancreatic-targeted lipid nanoparticles based on organ capsule filtration (AH-LNP) enabled precise Cas9 mRNA and sgRNA delivery to the pancreas, demonstrating therapeutic potential in autoimmune pancreatic diseases. Extrahepatic gene editing was achieved using organic solvent-free lipid nanoparticles capable of transfecting primary human immune cells and supporting CRISPR-Cas9 applications beyond the liver.

A composite ionic liquid-mediated transdermal platform (CIL-RNP) delivered CRISPR-Cas9 ribonucleoprotein complexes to keratinocytes for GLUT1 gene editing, ameliorating psoriasis in a topical application model. For HIV-1, a bipolar CD4-targeted dual-DARPin-55/57 lipid nanoparticle enabled CRISPR-Cas-mediated HIV-1 DNA excision and reactivation blockade in latent CD4 T cells. Mesoporous silica nanoparticles (MCM-41) modified with lysine and cysteine were employed for CRISPR-Cas9 plasmid delivery targeting the C-C motif chemokine ligand 2 (CCL2/MCP-1) gene. A NIR-II biomimetic nanoplatform delivered CRISPR-Cas9 plasmids alongside photothermal polymers for optogenetic CD274 editing in head and neck squamous cell carcinoma immunotherapy. The overarching principle across these delivery studies—that transient expression of CRISPR machinery suffices to achieve lasting therapeutic effects due to the permanent nature of genome editing—has guided the design of these platforms toward short-duration delivery with durable genomic outcomes.

Agricultural and Model Organism Applications

CRISPR-Cas9 has been widely applied in plant biology for crop improvement. Studies in tomato used CRISPR-Cas9 to knock out SlD27, SlCCD7, SlCCD8, and SlMAX1, elucidating their roles in strigolactone biosynthesis and parasitic weed resistance. CRISPR-Cas9-mediated knockout of VviBR6OX1 in grapevine recreated brassinosteroid-based dwarf phenotypes, confirming the gene's role in vine architecture. In Kam sweet rice, cis-regulatory editing (CRE editing) of the SD1 promoter via CRISPR-Cas9 strengthened TCP19-mediated repression to optimize plant height through modulation of gibberellin biosynthesis. A synthetic guide RNA scaffold enhanced CRISPR-Cas9 editing efficiency across multiple gene targets in plants. In Arabidopsis, CRISPR-based mosaic analysis was refined using patterned DNA nicks to reduce cytotoxicity associated with DSBs. In silkworm (Bombyx mori), CRISPR-Cas9-mediated knockout of BmGrh revealed its role in adult wing development. In Daphnia, CRISPR-Cas9 was established as a robust tool for loss-of-function research in this emerging aquatic model organism. Anolis lizards were edited via surgical oocyte injection of CRISPR-Cas9 ribonucleoprotein complexes, extending the reach of genome editing to non-traditional vertebrate models.

In microbiology, CRISPR-Cas9 was used to demonstrate that a mutation in mre11—a gene critical for genomic stability—underlies an accelerated mutator phenotype in a clinical Aspergillus fumigatus isolate, contributing to adaptive evolution and antifungal resistance. CRISPRi systems were deployed in methanotrophic bacteria for functional genomic screening of genes essential for methane-dependent growth, and cross-strain transferability of CRISPRi was evaluated in clinical Escherichia coli strains. In Mycobacterium tuberculosis, a genome-wide CRISPRi screen in an ex vivo intracellular model identified temporally dependent gene essentiality across infection stages. CRISPR-Cas9 and cytidine base editing systems were established in oleaginous Rhodococcus using NHEJ, eliminating the need for donor DNA templates. Multiplex genome editing in Acremonium chrysogenum was enabled by a tRNA-gRNA array-based CRISPR-Cas9 platform. Polyvalent guide RNAs were used with CRISPR enzymes to target and deplete human coronavirus nucleic acids, exemplifying CRISPR antiviral biotechnologies.

Diagnostic and Sequencing Applications

Beyond editing, the CRISPR toolkit has been extended to diagnostics and sequencing. CRISPR-Cas12a's collateral single-stranded DNA cleavage activity has been engineered for programmable spatiotemporal control, enabling next-generation diagnostics. Nanopore adapter-enriched Cas9-targeted sequencing (nAECATS) was developed for inexpensive, ultra-deep, selective long-read sequencing of targeted genomic regions in native, unamplified DNA. CRISPR-based dynamic barcoding (scDynaBar) was combined with single-cell sequencing to capture dynamic cellular processes at single-cell resolution. A DisTAL-Seq method—a TALEN-specific adaptation of DISCOVER-Seq—was developed to profile off-target activity of clinically relevant TALENs, with the CRISPR-Cas system's well-characterized target recognition serving as the comparative benchmark. High-resolution genotype-free mapping of genetic variation using CRI-SPA-Map combined CRISPR-Cas9 genome engineering with selective ploidy ablation and high-throughput phenotyping.

Off-Target Effects and Specificity Optimization

Off-target activity remains a central safety concern. Studies have investigated whether genomic R-loops (RNA/DNA hybrids) are associated with differences in Cas9-mediated genome editing outcomes, finding that endogenous R-loop topology at target sites may influence HDR efficiency. Optimal CRISPR-Cas9 knockout library design has been examined through systematic balancing of off-target and on-target considerations. Fully computational design using the UniDesign framework produced PAM-relaxed Staphylococcus aureus Cas9 variants with expanded targeting capability, addressing the PAM constraint that limits targetable genomic space. For epidermolysis bullosa, Cas9 nickases were highlighted as a strategy to mitigate off-target genotoxicity.